PFIZER INC (PFE) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating using this strategy is 85% based on the firm’s underlying fundamentals and the stock’s valuation.

For the current quarter, Pfizer is expected to post earnings of $0.48 per share, indicating a change of +380% from the year-ago quarter. The Zacks Consensus Estimate has changed -3.7% over the last 30 ...

Johnson & Johnson offers safer payouts and stronger growth. Discover why JNJ stock is the better dividend option compared to ...

We recently compiled a list of the 10 Best January Dividend Stocks To Buy. In this article, we are going to take a look at ...

FDA updates safety labels for Pfizer's Abrysvo and GSK's Arexvy RSV vaccines, citing increased Guillain-Barré syndrome risk.

Moderna/Merck partnership and its potential in personalised cancer therapies are good opportunities for long-term investors.

Here are four large-cap value stocks that growth and income investors may want to consider now. History suggests they will ...

Every investor in Pfizer Inc. ( NYSE:PFE) should be aware of the most powerful shareholder groups. We can see that ...

Pfizer Inc. (NYSE:PFE – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the sixteen ratings ...

On Friday, Pfizer Inc (PFE) stock saw a decline, ending the day at $26.59 which represents a decrease of $-0.02 or -0.08% from the prior close of $26.61. The stock opened at $26.7 and touched a low of ...